Novo Nordisk announces DKK 15B share repurchase program Novo Nordisk initiated a share repurchase program in accordance with the provisions of the European Commission's regulation no 2273/2003 of December 22, 2003. This program is part of the overall share repurchase program of up to DKK 15B to be executed during a 12-month period beginning January 30.
Novo Nordisk gets FDA approval for diabetes mellitus treatments The U.S. FDA announced that it approved Tresiba and Ryzodeg 70/30 to improve blood sugar control in adults with diabetes mellitus. Tresiba is a long-acting insulin analog indicated to improve glycemic control in adults with type 1 and 2 diabetes mellitus. Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog. It is indicated to improve glycemic control in adults with diabetes mellitus. Tresiba and Ryzodeg are manufactured by Novo Nordisk.